Skip to main content

Table 3 PsA treatment at study visit

From: Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study

  Total MDA No MDA p
Treatment pattern, n (%)     NS
 Anti-TNF monotherapy 110 69 (62.7) 41 (37.3)  
 DMARDS and anti-TNF 61 32 (52.5) 29 (47.5)  
 DMARDS monotherapy 51 32 (62.7) 19 (37.3)  
Anti-TNF*, n (%) 112 64 (57.1) 48 (42.9) NS
 Etanercept 42 26 (61.9) 16 (38.1)  
 Adalimumab 35 22 (62.9) 13 (37.1)  
 Infliximab 15 6 (40.0) 9 (60.0)  
 Golimumab 13 7 (53.8) 6 (46.2)  
 Mean (SD) time, months 45.7 (34.7) 50.5 (35.0) 40.2 (33.8) NS
DMARDS*, n (%) 171 101 (59.1) 70 (40.9) NS
 Metotrexate 130 76 (58.5) 54 (41.5)  
 Leflunomide 32 17 (53.1) 15 (46.9)  
 Mean (SD) time, months 73.7 (70.4) 71.8 (71.8) 76.4 (69.7) NS
NSAIDs**, n (%) 114 62 (54.4) 52 (45.6) NS
Infiltrations**, n (%) 48 27 (56.3) 21 (43.8) NS
Corticoids**, n (%) 39 16 (41.0) 23 (59.0) <0.05
  1. *Monotherapy or combination therapy
  2. **Combination therapy
  3. anti-TNF anti-tumor necrosis factor, DMARDS disease-modifying anti-rheumatic drugs, NS not significant, NSAIDs nonsteroidal anti-inflammatory drugs